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Abstract
The study objective was to delineate the genetics of inherited retinal degenerations
(IRDs) in Iceland, a small nation of 364.000 and a genetic isolate. Benefits include
delineating novel pathogenic genetic variants and defining genetically homogenous
patients as potential investigative molecular therapy candidates. The study sample
comprised patients with IRD in Iceland ascertained through national centralized
genetic and ophthalmological services at Landspitali, a national social support insti-
tute, and the Icelandic patient association. Information on patients' disease, syn-
drome, and genetic testing was collected in a clinical registry. Variants were
reevaluated according to ACMG/AMP guidelines. Overall, 140 IRD patients were
identified (point prevalence of 1/2.600), of which 70 patients had a genetic evalua-
tion where two-thirds had an identified genetic cause. Thirteen disease genes were
found in patients with retinitis pigmentosa, with the RLBP1 gene most common
(n = 4). The c.1073 + 5G > A variant in the PRPF31 gene was homozygous in two RP
patients. All tested patients with X-linked retinoschisis (XLRS) had the same possibly
unique RS1 pathogenic variant, c.441G > A (p.Trp147X). Pathologic variants and
genes for IRDs in Iceland did not resemble those described in ancestral
North-Western European nations. Four variants were reclassified as likely patho-
genic. One novel pathogenic variant defined a genetically homogenous XLRS patient
group.
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1 | INTRODUCTION
Inherited retinal degenerations (IRDs) are a large group of diseases,
which are both clinically and genetically heterogeneous.1,2 IRD affects
the retina, a specialized, light-sensitive nervous tissue, and the inner-
most layer of the eye.3 The photoreceptors are most commonly
affected.1 Collectively, these diseases are among the leading causes
for blindness worldwide,4,5 with an estimated prevalence of about 1/
2.000–1/3.000.6
A total of 271 genes are known to cause IRDs.7 Their protein
products function in various biological pathways, such as eye develop-
ment, the retinal cells' structure, phototransduction, regeneration of
Received: 29 November 2020 Revised: 7 April 2021 Accepted: 10 April 2021
DOI: 10.1111/cge.13967
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
156 Clinical Genetics. 2021;100:156–167.wileyonlinelibrary.com/journal/cge
the retinoid substance, retinal enzymatic function, and photoreceptor
survival.2 Despite the number of known disease genes, the genetic
causality can only be identified in about two-thirds of IRD
patients.1,2,8 IRDs are almost always inherited by monogenic inheri-
tance, where the disease gene comes from either parent or both, and
by mitochondrial inheritance, from mother to child.4 IRDs can also
rarely be inherited by digenic inheritance.9 IRD can affect the whole
retina or a specific portion of it, for example, the macula. Either rods
or cones, or both, can be affected, and the visual effect can be either
night blindness and loss of visual field, loss of color sensation and cen-
tral vision, or both. IRD can be restricted to the retina, or it can be part
of a more extensive syndrome.4 The most common IRDs are retinitis
pigmentosa (RP), non-syndromic and syndromic, Stargardt disease,
X-linked retinoschisis (XLRS), achromatopsia, choroideremia, and
Leber congenital amaurosis.10
The genetics of IRDs as a group has not been described before in
Iceland, a nation of approximately 364.000,11 and descendants of Nor-
dic and Gaelic populations.12 As the genetics of IRDs is gradually being
elicited, it is important to report the genetics of IRDs in small nations,
especially genetic isolates like Iceland. In small populations, it can some-
times be easier to evaluate pathogenic variants. In a small nation a group
of patients can be defined with the same pathogenic variant, which
would be optimal for future molecular therapies. In Iceland, the genetics
of IRDs is limited to a study on the genetics of Sveinsson's chorioretinal
atrophy (SCRA), also referred to as helicoid peripapillary chorioretinal
degeneration or atrophia areata. SCRA is substantially common in the
Icelandic population, with about 116 patients diagnosed.13 Interestingly,
every reported patient with SCRA in other countries has an Icelandic
ancestry.13 Thus, this study did not include that disease.
Knowing the genetic causes for IRDs improves understanding of
prognosis for individual patients and facilitates the identification
of relatives at risk. A genetic diagnosis also allows reproductive
choices with either a preimplantation or prenatal genetic diagnosis.
Knowledge of the genetic causes of IRDs is also necessary for Icelan-
dic IRD patients to participate in clinical trials in genetic and molecular
therapies and to benefit from them as they become available. Our
study aimed to delineate the genetic causes of IRDs in Icelandic
patients by summarizing the results of genetic evaluations.
2 | MATERIALS AND METHODS
2.1 | Patient inclusion criteria
This study used the Retinal Information Network (RetNet)7 informa-
tion bank about the genetics of IRDs. All patients were diagnosed by
an ophthalmologist. Diagnosis methods generally included
fundoscopic examination, slit lamp (biomicroscope) examination,
visual field testing, ERG testing, and recently optical coherence
tomography. Patients were included if their phenotype matched an
IRD and if they had previously undergone a genetic evaluation by a
medical geneticist for disease genes registered at RetNet. Patients
were excluded if the reason for a genetic evaluation was a differential
diagnosis and their phenotype did not match IRD. SCRA patients were
excluded from the study, both in the description of genetic findings
and prevalence calculations. Both patients and their family members,
that underwent a genetic evaluation for risk assessment and segrega-
tion analyses, were registered in the study's data registry.
2.2 | Patient ascertainment
The study's sample comprised all patients with IRD that had under-
gone a genetic evaluation at the Department of Genetics and Molecu-
lar Medicine (GMM) at Landspitali- National University Hospital. A
systematic search was performed at the GMM, dating back to the
year when the department was established in 2002.
A registry of visual electrophysiological recordings performed
on patients at the Department of Ophthalmology at Landspitali
was accessed, which included electroretinograms (ERG) and elec-
trooculograms (EOG). That electrophysiology registry consisted of
every ERG and EOG recording since the first test was performed in
Iceland in 1991. These recordings were obtained in compliance
with the International Society for Clinical Electrophysiology of
Vision (ISCEV) standards for these procedures in force at each
given time.
An ICD10 code search was also performed, using H35.5
(Hereditary Retinal Dystrophy) and Z82.1 (Family History of Blindness
and Visual Loss). The ICD10 search was performed at Landspitali,
Akureyri Hospital, and the Icelandic National Institute for the Blind,
Visually Impaired, and Deafblind, also referred to as the Center. A reg-
istry of members with RP at Blindrafelagid, the Icelandic Association
of Visually Impaired (BIAVI), was also obtained.
2.3 | Data registry
A data registry was assembled for this study, comprising patients'
medical information. Data collected were ophthalmic medical records,
especially diagnosis, other medical issues, genetic evaluation results,
and patient's family history. The data registry was sorted by disease
diagnosis with 18 different variables assigned to each patient. These
variables were patient's name, social security number, gender, diagno-
sis, year of diagnosis by a genetic evaluation, age of diagnosis by a
genetic evaluation, disease gene, inheritance, NCBI reference code,
genetic variant, biochemical consequences, genotype, pathogenic clas-
sification, type of genetic test, phenotype, ERG results, parental test-
ing, and family history.
In this study, patients were classified as to whether they had
(1) a known genetic cause, (2) an unclear result, or (3) no identified
genetic cause. A genetic cause was defined if a patient had two
pathogenic/ likely pathogenic (P/LP) variants in trans, causing auto-
somal recessive (AR) disease, one P/LP pathogenic variant that cau-
ses autosomal dominant (AD) disease, a P/LP variant in an X-linked
disease among males, and a P/LP variant in mitochondrial inheri-
tance. An unclear result was defined if only one heterozygous P/LP
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TABLE 1 Overview of RP patients
Patient Phenotype ERG Gene Inh Genotype Genetic Variant
Protein/ RNA
splicing Class ClinVar§§ gnomAD¶¶
RP1 RP. Symptoms 20 y Consistent with
RP.,,atypical
RP”
EYS AR Ht c.2620C>T p.Gln874* P¬ Yes 4e-5
RP2 RP. Symptoms 20 y Consistent with
RP
EYS AR Ht c.6725+1G>C Interferes with
splicing
LP No N/A








HGSNAT AR Ho c.1843G>A p.Ala615Thr LP Yes 3.82e-3
RP4 Early-onset RP, about 8 y Consistent with
RP
HK1 AD Ht c.626A>G p.Asp209Gly LP No N/A
RP5 Late-onset RP, symptoms




OTX2 AD Ht c.106G>C p.Ala36Pro VUS No N/A
IFT172 AR Ht c.4907_4908del p.His1636Argfs*5 P¬ No N/A
RP6 Early-onset RP, diagnosed
22 y
N/A PDE6A AR Ht c.2053G>A p.Val685Met LP Yes 3e-5
PDE6A AR Ht c.1621-6T>G Could affect
splicing
LP No N/A
RP7 Early-onset RP, diagnosed
about 20 y
N/A PDE6A AR Ht c.2053G>A p.Val685Met LP Yes 3e-5
PDE6A AR Ht c.1621-6T>G Could affect
splicing
LP No N/A
RP8 Early-onset RP, diagnosed
12 y
N/A PDE6B AR Ho c.1685G>A p.Gly562Asp LP Yes 3e-5




PRPF31 AD Ho c.1073+5G>A Could affect
splicing
LP Yes 1,1e-4




PRPF31 AD Ho c.1073+5G>A Could affect
splicing
LP Yes 1,1e-4
RP11 Early-onset RP Consistent with
RP
RHO AD Ht c.1040C>T p.Pro347Leu P Yes 3e-5




RLBP1 AR Ht c.677T>A p.Met226Lys P Yes 3e-5
RLBP1 AR Ht c.832C>T p.Gln278* P No N/A




RLBP1 AR Ht c.677T>A p.Met226Lys P Yes 3e-5
RLBP1 AR Ht c.832C>T p.Gln278* P No N/A
RP14 RP, onset of symptoms at
20-30 y
N/A RLBP1 AR Ht c.677T>A p.Met226Lys P Yes 3e-5
RLBP1 AR Ht c.832C>T p.Gln278* P No N/A




RLBP1 AR Ho c.832C>T p.Gln278* P No N/A
RP16 RP, diagnosed 27 y N/A RP1 AR Ho c.491C>G p.Pro164Arg VUS Yes N/A
RP17 RP, diagnosed 20 y N/A RPE65 AR Ht c.1409C>G p.Pro470Arg LP¬ No N/A
PRPF8 AD Ht c.37C>G p.Pro13Ala VUS Yes N/A
Note: The additional sign “ ¬ ” indicates that the association of the genetic variant with patient's disease is unclear, §§ Variant reported in ClinVar, ¶¶Allele
frequency reported in gnomAD.
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CAR, cancer-associated retinopathy; ERG, electroretinogram; EYS, NM_001292009.1;
Hemiz, hemizygous; Heteropl, heteroplasmic; HGSNAT, NM_152419.2; HK1, NM_000188.2; Ho, homozygous; Homopl, homoplasmic; Ht, heterozygous;
IFT172, NM_015662.2; Inh, inheritance; LP, likely pathogenic; MAR, melanoma-associated retinopathy; Mito-inh, mitochondrial inheritance; N/A, not
available; OTX2, NM_001270525.1; P, pathogenic; PDE6A, NM_000440.2; PDE6B, NM_000283.3; PRPF31, NM_015629.3; PRPF8: NM_006445.3; RF, risk
factor; RHO, NM_000539.3; RLBP1, NM_000326.4; RP, retinitis pigmentosa; RP1, NM_006269.1; RPE65: NM_000329.2; VUS, variant of unknown
significance; XL-D, X-linked dominant; XL-R, X-linked recessive.
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variant was identified that causes AR disease, a variant of unknown
significance (VUS) was identified that causes AD disease, a VUS
was identified that causes X-linked disease among males, and a
VUS identified in mitochondrial DNA. No identified genetic cause
was defined if there were no identified VUS or P/LP variants, if
only a single heterozygous VUS was identified in AR disease, and if
there were VUS identified in a disease gene that did not match the
patient's phenotype.
Variants excluded from the tables were single heterozygous VUS for
AR diseases unless another P/LP variant, or VUS was identified also in
the same gene. Variants with a higher allele frequency than 1% were not
reported in the tables except in case of a well-known risk factor.







splicing Class ClinVar§§ gnomAD¶¶
SD1 SD, diagnosed
6 y
N/A 5 Ht c.634C>T p.Arg212Cys P Yes 6e-5





6 Ht c.768G>T p.Val256Val P Yes 9e-5





N/A 6 Ht c.768G>T p.Val256Val P Yes 9e-5









6 Ht c.768G>T p.Val256Val P Yes 9e-5







6 Ht c.768G>T p.Val256Val P Yes 9e-5












6 Ht c.768G>T p.Val256Val P¬ Yes 9e-5
SD8 SD, diagnosed
13 y
N/A 11 Ho c.1622T>C p.Leu541Pro p Yes 1.5e-4






27 Ht c.4179del p.lle1394Serfs*10 LP No N/A











38 Ht c.5461-10T>C Affects introns P 2.20e-4
Note: ΔInheritance pattern is autosomal recessive.
Abbreviations: ABCA4, NM_000350.2; AD, autosomal dominant; AR, autosomal recessive; CAR, cancer-associated retinopathy; ERG, electroretinogram;
EYS, NM_001292009.1; Hemiz, hemizygous; Heteropl, heteroplasmic; HGSNAT, NM_152419.2; HK1, NM_000188.2; Ho, homozygous; Homopl,
homoplasmic; Ht, heterozygous; IFT172, NM_015662.2; Inh, inheritance; LP, likely pathogenic; MAR, melanoma-associated retinopathy; Mito-inh,
mitochondrial inheritance; N/A, not available; OTX2, NM_001270525.1; P, pathogenic; PDE6A, NM_000440.2; PDE6B, NM_000283.3; PRPF31,
NM_015629.3; PRPF8: NM_006445.3; RF, risk factor; RHO, NM_000539.3; RLBP1, NM_000326.4; RP, retinitis pigmentosa; RP1, NM_006269.1; RPE65:
NM_000329.2; SD, Stargardt disease; VUS, variant of unknown significance; XL-D, X-linked dominant; XL-R, X-linked recessive.
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2.4 | Informatics and analysis
The standard protocol at the GMM for genetic testing for IRD
patients is comprehensive retinal dystrophy panel sequencing in a
leading clinical laboratory with an increasing number of genes tested
over time. Lately, testing has been based on in silico extraction from
whole-exome sequencing data and dup/del evaluation using data
from next-generation sequencing. Specific testing for structural vari-
ants was not done. Co-segregation analysis and de novo testing were
recommended and done on accessible relatives.
To determine the significance of genetic variants, we used
the Alamut Visual v.2.14 software (https://www.interactive-
biosoftware.com/alamut-visual/), VarSome,14 Human Genome
Mutation Database (HGMD) Professional 2020.1,15 Genome
Aggregation Database (gnomAD),16 and ClinVar.17 The Online
Mendelian Inheritance in Man (OMIM)18 database was used to
obtain information about disease genes and their associated
phenotypes. The American College of Medical Genetics and
Genomics (ACMG) and The Association for Molecular Pathol-
ogy (AMP) guidelines19 were used to classify genetic variants.
Information about the most recent population count on
January 1, 2020, was obtained from the Institution of Statistics
in Iceland.11 A confidence level of 95% was used to estimate
confidence intervals (CI) for prevalence calculations. The Ice-
landic Genealogical Database20 was used to determine if
patients were related.
2.5 | Permission
This study was granted permission by the National Bioethics Commit-
tee in Iceland (NBC). Reference number 20-012-V1. Patients' personal
information was treated in concordance with the regulation from the
Data Protection Authority in Iceland.
3 | RESULTS
Overall, 140 IRD patients were identified, of which 1 was deceased,
yielding a point prevalence in Iceland of 1/2.600 (CI: 1/3.100–
1/2.250). Of those 70 patients, in 58 families, had undergone a
genetic evaluation. No additional patients with a genetic evaluation
were ascertained when the ICD10 lists and the list from the BIAVI
were reviewed. These additional searches were done to confirm that
TABLE 3 Overview of LHON patients















































Homopl m.15446C>T p.Leu234Phe VUS Yes 1.77e-5
Note: §§ Variant reported in ClinVar, ¶¶Allele frequency reported in gnomAD.
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CAR, cancer-associated retinopathy; ERG, electroretinogram; EYS, NM_001292009.1;
Hemiz, hemizygous; Heteropl, heteroplasmic; HGSNAT, NM_152419.2; HK1, NM_000188.2; Ho, homozygous; Homopl, homoplasmic; Ht, heterozygous;
IFT172, NM_015662.2; Inh, inheritance; LP, likely pathogenic; MAR, melanoma-associated retinopathy; Mito-inh, mitochondrial inheritance; N/A, not
available; OTX2, NM_001270525.1; LHON, Leber hereditary optic neuropathy; MT-CYB, YP_003024038.1; MT-ND1, YP_003024026; P, pathogenic;
PDE6A, NM_000440.2; PDE6B, NM_000283.3; PRPF31, NM_015629.3; PRPF8: NM_006445.3; RF, risk factor; RHO, NM_000539.3; RLBP1,
NM_000326.4; RP, retinitis pigmentosa; RP1, NM_006269.1; RPE65: NM_000329.2; VUS, variant of unknown significance; XL-D, X-linked dominant;
XL-R, X-linked recessive.
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no IRD patient had been missed after the search at the GMM and
after reviewing the Electrophysiology registry. GMM, Electrophysiol-
ogy at the Department of Ophthalmology, the Center, and BIAVI are
the only institutions in Iceland that provide these types of services,
thus suggesting a very high ascertainment. The number of family
members tested at the GMM was 45, and the number of patients at
the GMM that have not yet undergone a genetic evaluation was 5.
The genetic tests were done from 2004 to October 2020. Most
patients were tested between 2015 and 2020. The number of differ-
ent IRD diseases registered at the GMM was 20. Non-syndromic RP
was the most common diagnosis, followed by Stargardt disease, Leber
hereditary optic neuropathy (LHON), X-linked retinoschisis, and Usher
syndrome.
3.1 | Non-syndromic RP
Sixty-three alive patients had RP, yielding a point prevalence of
1/5.800 (CI: 1/7.700–1/4.650). Nineteen had undergone a genetic
evaluation, of which 13 had a genetic cause for their disease
(Table 1), five had an unclear result, and one had no identified
genetic cause. The number of disease genes found in patients with
RP was 13. Variants in the RLBP1 gene was most common (n = 4).
The most common variant in the RLBP1 gene was c.832C > T, found
once in a homozygous state and three times in a heterozygous state.
The second most common variant in the RLBP1 gene was
c.677 T > A, found three times in a heterozygous state with the
c.832C > T variant. Patients RP9 and RP10 had the same genetic
variant in a homozygous state, NM_015629.3(PRPF31):c.1073
+ 5G > A. According to ACMG/AMP guidelines, this variant was
reclassified by the GMM as likely pathogenic (ACMG/AMP score:
PS4, PM2, PP1, PP3). Patients RP9 and RP10 were not related.
Patient RP3 had the genetic variant NM_152419.2 (HGSNAT):
c.1843G > A:(p.Ala615Thr) in a homozygous state and patient RP17
had the genetic variant NM_000329.2 (RPE65):c.1409C > G:(p.
Pro470Arg) in a heterozygous state. These genetic variants were
reclassified as likely pathogenic (ACMG/AMP score for (HGSNAT):
c.1843G > A: PS4, PP2, PP3) (ACMG/AMP score for (RPE65):
c.1409C > G: PM1, PM2, PM5, PP2, PP3). Patients with an unclear
result in Table 1 were RP1, RP5, RP16, and RP17.
TABLE 4 Overview of patients with Usher syndrome









N/A ADGRV1 AR Ho c.9140T>G p.Leu3047* P No N/A
US2 USH2A, hearing
impairment 3-4 y,
RP about 25 y
Consistent
with RP
USH2A AR Ht c.5907C>G p.Tyr1969* P No N/A








USH2A AR Ht c.13316C>T p.Thr4439lle P Yes 2e-5
USH2A AR Ht c.10601A>G p.Tyr3534Cys LP No N/A








USH2A AR Ht c.13316C>T p.Thr4439lle P Yes 2e-5
USH2A AR Ht c.10601A>G p.Tyr3534Cys LP No N/A
USH2A AR Ht c.10564A>G p.Arg3522Gly VUS Yes 2.5e-4
Note: §§ Variant reported in ClinVar, ¶¶Allele frequency reported in gnomAD.
Abbreviations: ABCA4, NM_000350.2; AD, autosomal dominant; AR, autosomal recessive; CAR, cancer-associated retinopathy; ERG, electroretinogram;
EYS, NM_001292009.1; Hemiz, hemizygous; Heteropl, heteroplasmic; HGSNAT, NM_152419.2; HK1, NM_000188.2; Ho, homozygous; Homopl,
homoplasmic; Ht, heterozygous; IFT172, NM_015662.2; Inh, inheritance; LP, likely pathogenic; MAR, melanoma-associated retinopathy; Mito-inh,
mitochondrial inheritance; N/A, not available; OTX2, NM_001270525.1; P, pathogenic; PDE6A, NM_000440.2; PDE6B, NM_000283.3; PRPF31,
NM_015629.3; PRPF8: NM_006445.3; RF, risk factor; RHO, NM_000539.3; RLBP1, NM_000326.4; RP, retinitis pigmentosa; RP1, NM_006269.1; RPE65:
NM_000329.2; SD, Stargardt disease; USH2A, Usher Syndrome Type 2A; USH2C, Usher Syndrome Type 2C; ADGRV1: NM_032119.3; USH2A:
NM_206933.2; VUS, variant of unknown significance; XL-D, X-linked dominant; XL-R, X-linked recessive.
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3.2 | Stargardt disease
Twenty-one alive patients had Stargardt disease, yielding a point
prevalence of 1/17.000 (CI: 1/30.000–1/12.000). Eleven had under-
gone a genetic evaluation, of which seven had a genetic cause, but
four had an unclear result. Three had only one genetic variant,
patients SD6 and SD7 in Table 2. The third patient had a VUS. The
most common variants in the ABCA4 gene were missense variants
(n = 9, pathogenic n = 7), variants that affect splicing (n = 3), which
were both pathogenic, and a deletion (n = 1), which was pathogenic.
The most common variant was c.768G > T. That variant was found
six times, every time in a heterozygous state, four times with another
variant, and two times where it was the only variant that was found
(Table 2).
3.3 | Leber hereditary optic neuropathy
Six alive patients had LHON disease, yielding a point prevalence of
1/60.000 (CI: 1/304.000–1/34.000). Four patients had a genetic
cause (Table 3). All had the same pathogenic variant, m.3460G > A:
(p.Ala52Thr) in the MT-ND1 gene, which is one of three most com-
mon genetic variants in LHON worldwide.21 The patients with this
pathogenic variant were all related. One patient, LHON5 (Table 3),
had a variant of unknown significance in the MT-CYB gene. One
patient had a clinical diagnosis of the disease but no identified
genetic cause.
3.4 | X-linked retinoschisis
Thirteen alive patients had XLRS, yielding a point prevalence of
1/28.000 (CI: 1/61.000–1/18.000). Of those 13 patients, five had
undergone a genetic evaluation. These patients belonged to three
families, where two families had a common ancestor in the 19th cen-
tury. The patient that belonged to the third family was not related to
the other two families. Every patient that underwent a genetic evalua-
tion had the same genetic variant on the X chromosome, c.441G > A:
(p.Trp147X) in the RS1 gene.
3.5 | Usher syndrome
Nine alive patients had Usher syndrome, yielding a point prevalence
of 1/40.000 (CI: 1/117.000–1/24.00). Of those nine patients, four
had undergone a genetic evaluation. Three patients had the USH2A
phenotype and variants in the USH2A gene (Table 4). Of those three,
two patients, US3 and US4, had a variant of unknown significance,
the variant NM_206933.2(USH2A):c.10601A > G:(p.Tyr3534Cys). The
variant was reclassified as a likely pathogenic variant according to
ACMG/AMP guidelines (ACMG/AMP score: PM1, PM2, PM3, PP2,
PP3). One patient had the USH2C phenotype and variants in the
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3.6 | Other IRDs
Twenty-four patients had 15 other IRDs diseases and a genetic
evaluation. Of those 24 patients, 14 had a genetic cause, five had
an unclear result, and five had no identified cause (Table 5). Two
patients had choroideremia but had been previously diagnosed
with RP. Three patients had X-linked congenital stationary night
blindness (XLCSNB) and had the same hemizygous variant,
NM_005183.2 (CACNA1F): c.1685-1G > C. These patients with
XLCSNB were all related.
4 | DISCUSSION
In this study, we delineated the genetic causes of IRDs in Icelandic
patients by summarizing their genetic evaluation results. Our results
showed that out of 70 patients that had undergone a genetic evalua-
tion, about two-thirds had an identified genetic cause, similar to the
proportion reported worldwide.1,2,8 The prevalence of IRDs in Iceland
is about 1/2.600, also similar to the reported world prevalence.6
The prevalence of RP is estimated to be about 1/5.800 in Iceland,
which is similar to reported world prevalence, 1/4.000.22,23 However,
previous studies have reported that the average prevalence in Ameri-
can and European populations is 1/5.260.24 In contrast, prevalence
has been reported as high as 1/2.000 in Våsterbotten-county in
Northern Sweden.25 A total of 13 disease genes were found in Icelan-
dic patients, and the most common disease gene was RLBP1 (n = 4). A
Norwegian study reported a total of 23 different disease genes in
468 RP patients, and among them was the RLBP1 gene (n = 2). The
variant c.677 T > A in the RLBP1 gene was also reported in Norwegian
patients, both in a heterozygous and homozygous form.26 The
c.832C > T variant has been reported exclusively in the European
population.27 The variant c.677 T > A has also exclusively been
reported in the European population with allele frequency even higher
than the c.832C > T variant.27 A Danish study reported a total of
32 disease genes in 294 RP patients, among them was the RLPB1
gene (n = 2). However, the most common gene in Danish patients
was USH2A (n = 41),28 the most common disease gene in AR RP
worldwide.23 An Irish study reported that the most common disease
gene in Irish patients with RP was RHO,29 which is also the most com-
mon in AD RP worldwide.23 A Japanese study reported that the most
common disease gene in Japanese patients with RP is EYS,30 which is
also common in Chinese and Spanish patients.31
Patients RP9 and RP10 were homozygous for the same genetic
variant NM_015629.3 (PRPF31): c.1073 + 5G > A. This variant has
been reported in Danish patients with RP, in a heterozygous state
with a different VUS.28 Alamut Visual v.2.14 predicts that this variant
affects splicing of the mRNA transcript. The allele frequency of this
variant worldwide is low, about 0,011%, according to gnomAD. Inter-
estingly, the allele frequency of this variant in the Icelandic population
is substantially higher, about 0,24% (Patrick Sulem, personal commu-
nication). The estimated number of heterozygotes in Iceland for this
variant is about 1.750. However, pathogenic variants in the PRPF31
gene cause AD RP (OMIM: 606419). A co-segregation analysis had
been performed on patient's RP10 unaffected siblings, a total of six.
Five were heterozygous for the variant, and one was not a carrier,
consistent with an AR inheritance pattern. We assume that this vari-
ant causes AR RP because of a hypomorphic allele effect and was
accounted for in the ACMG/AMP classification. However, this is a
hypothesis not corroborated by experimental data. Blueprint Genetics
has previously reported finding three patients with RP and homozy-
gous for the c. 1073 + 5G > A. Another splicing variant c.855
+ 3G > C is also assumed to cause AR RP.32
Patient RP17 had a heterozygous VUS in the PRPF8 gene, which
causes AD RP (OMIM: 607300), and a newly reclassified LP
c.1409C > G variant in the RPE65 gene, which causes AR RP (OMIM:
180069). The variant in the PRPF8 gene was the most rational choice
for a possible genetic cause. However, there have been reports of a
genetic variant in the RPE65 gene causing AD RP, the variant
c.1430G > A (p. Asp477Gly).33-35 In 2005, Takahashi et al. showed
that if the glutamic acid positioned at 469 in RPE65 protein was
substituted with alanine or glutamine, then the enzymatic activity
was reduced.36 However, the patient's RP17 family history and dis-
ease pattern do not support a dominant disease. Yet, there have been
reports that dominant variant expressions in the RPE65 gene can vary
between individuals, from non-penetrance to severe, resembling
choroideremia.37
Patient RP3 was homozygous for the variant c.1843G > A:(p.
Ala615Thr) in the HGSNAT gene, which was reclassified as likely path-
ogenic by us. This variant has been described by Schiff et al. in a
homozygous state in patients with late-onset RP, but with incomplete
penetrance.38 Presumably, unidentified factors affect penetrance for
the disease in these patients.
Patient RP1 was heterozygous for a pathogenic variant in the EYS
gene and three different variants of unknown significance in the
PROM1, ABCA4, and PDE6B genes (not in Table 1), all known to cause
recessive RP (OMIM: 604365; 601691; 180072). However, digenic
inheritance in the EYS gene and CDH23 gene has been reported in a
patient with RP and a mild hearing impairment.28 Since digenic inheri-
tance has been described,9 one or more VUSs in patient RP1 could
possibly augment the pathogenic effect of the variant in EYS, resulting
in RP phenotype.
The most common genetic variants in the ABCA4 gene in
Stargardt disease were missense variants, about 70% (54% if only
pathogenic and likely pathogenic variants were considered). This pro-
portion, 70%, is similar to what has been reported worldwide.39 The
most common variant was c.768G > T, a variant also common in Dan-
ish, Dutch, Norwegian, and Swedish patients.26,28,40,41
Three patients had only one identified variant in the ABCA4 gene,
which is similar to the proportion found worldwide.39 Patients SD6
and SD7 were both heterozygous for the c.768G > T variant. They
had in common that their symptoms started at about 50 years of age
and their pattern ERG was flat. Multiple studies have suggested an
association between being heterozygous for only one variant in the
ABCA4 gene and developing age-related macular degeneration.42-44 In
2015, Kjellström reported that individuals who were heterozygous for
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the c.768G > T variant had signs of degeneration in the macula.41
However, in our study, one individual was heterozygous for the
c.768G > T variant, but did not have any ocular-related medical prob-
lems that could be discerned from his medical records. That individual
underwent a genetic evaluation to determine the significance of
genetic variants found in his family member. Also, patient SD2 was
heterozygous for the c.768G > T variant and the pathogenic missense
variant c.1964 T > G, and his symptoms were late-onset, at 70 years
of age. Thus, there is probably an unidentified variant in patients SD6
and SD7.
Patient SD9 was heterozygous for a pathogenic variant and the
c.5603A > T variant, which is considered a risk factor if it is in trans
with a pathogenic variant in ABCA4 gene.45 However, it has been
reported that penetrance of Stargardt disease is low in patients carry-
ing this variant in trans.46
Every patient with XLRS, which underwent a genetic evaluation,
had the same variant, NM_000330.3 (RS1): c.441G > A: (p.Trp147*),
also known as p.W147X. This alteration leads presumably to
nonsense-mediated mRNA decay. This variant was not in HGMD,
ClinVar, nor gnomAD databases. We assume this variant to be a
unique Icelandic variant. This is an example of the benefits of studying
the genetics of IRDs in a small population and a genetic isolate. These
patients could be potential candidates for future variant-specific
molecular therapy trials for XLRS, eliminating possible variability due
to genetic causation.
The most common disease genes in patients with Usher syn-
drome was USH2A (n = 3). A Danish study reported that USH2A is
also the most common disease gene in Danish patients with Usher
syndrome (n = 2).28 However, variants found in the Icelandic patients
were not found in Danish patients28 nor in Norwegian patients.26 The
variant c.13316C > T in the USH2A gene has been described exclu-
sively in the European population.27 The USH2A gene is also the most
common disease gene in Irish patients with Usher syndrome.29
4.1 | Limitations
World prevalence of Stargardt disease, Leber hereditary optic neurop-
athy, X-linked retinoschisis, and Usher syndrome is 1/8.000–
1/10.000,47 1/27.000–1/45.000,21 1/5.000–1/20.000,48,49 and
1/6.000,50 respectively. The study's calculated prevalence of these
diseases was lower. Four reasons could explain that. First, the ascer-
tainment was incomplete. However, the list of patients in the various
registries combined should closely reflect the number of patients in
Iceland. Second, these diseases could in reality be rarer in Iceland
because of a founder effect or a genetic drift enhanced by the small
population size and genetic isolation. Third, a misdiagnosis is possible,
but not likely, since the healthcare services, clinical workup, and
supervision of these patients are considered to be among the best in
the world.51 Fourth, the study's calculated prevalence could be a sta-
tistical coincidence, considering Iceland's small population compared
to other studies reporting-prevalence in larger populations.
The clinical parameters of the study sample do not suggest that
there was significant bias in what proportion of IRD patients have
undergone a genetic evaluation. About half of patients in every dis-
ease category of IRDs have undergone a genetic evaluation. However,
an ascertainment bias is possible regarding the age of patients having
had a genetic evaluation. New patients, including children, have in
recent years been referred for a genetic evaluation by an ophthalmol-
ogist. Middle-aged patients often undergo a genetic evaluation
because of concern for their children's risk. Other groups, that is, sta-
ble young adults and the elderly, are probably somewhat underrepre-
sented in the genetic evaluation group.
A major limitation of the study is that the genetic evaluations
were performed over a long period, about 16 years. Over the period
of the genetic evaluation in the study, the number of genes tested
were increased, and dup/del testing was introduced. Methods, tech-
nology, and the knowledge needed to accurately diagnose these
patients have become progressively advanced. The major limitations
of genetic tests today are that they do not diagnose variants in regula-
tory regions, deep intron sequence, and structural variants. When
genetic tests for these variants become clinically available, it might be
possible to delineate the genetics of patients with unclear results or
no identified genetic cause.
5 | CONCLUSIONS
IRDs in Iceland are a complex group of diseases with a heterogeneous
and unique genetic pattern, which could be explained by a founder
effect and a genetic drift. This contribution from a small genetically
isolated nation improves the world's knowledge of the molecular
genetics of IRDs. Because of our small population size, we could
reclassify two variants as likely pathogenic and therefore provide a
genetic cause for four patients. Our findings suggest that the variant
c.1073 + 5G > A in the PRPF31 gene possibly causes AR RP, and the
allele frequency is substantially higher in the Icelandic population
compared to the world. The variant c.441G > A in XLRS patients is
likely a unique Icelandic variant and was found in every genetically
tested XLRS patient. The potential benefit of defining a patient popu-
lation with the same pathogenic variant is that they could become
candidates for future molecular therapy trials.
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